Chai Discovery
AI drug-discovery company building multimodal foundation models and computer-aided design tools for molecular structure prediction and de novo therapeutic design.
$3.8B*192%increase
| Model | Family | Released | Modality | Open source | API | Status |
|---|---|---|---|---|---|---|
| Chai-3 | — | Jun 4, 2026 | — | — | — | partner access |
| Chai-2Family | — | Jun 30, 2025 | — | — | — | limited access |
| Chai-1 | — | Sep 9, 2024 | — | Yes | — | active |
* Market cap / valuation. Company values are AI-attributed: the latest market cap or valuation × the share attributed to AI (100% for pure AI companies). Methodology